|
Mean (SD) / Median (IQR) |
Missing |
Mean (SD) / Median (IQR) |
Missing |
Mean (SD) / Median (IQR) |
Missing |
A vs C |
B vs C |
Annualised rate of exacerbations, median (IQR) |
5 (3) † |
2 |
4 (5) † |
1 |
5 (3) ‡ |
32 |
0.391 |
0.744 |
Annualised rate of AHE, median (IQR) |
1 (2) † |
9 |
0 (1) † |
3 |
0 (1) ‡ |
1 |
0.238 |
0.184 |
Maximum Eos count in the past year, median (IQR) - cells/µL |
250 (400) † |
9 |
500(400) † |
0 |
200 (300) ‡ |
49 |
0.052 |
<0.001 |
ACQ6, median (IQR) |
3 (1.79) § |
25 |
2.67 (1.67) § |
3 |
3
(1.8) ‡ |
11 |
0.594 |
0.795 |
FENO, median (IQR) - ppb |
30 (38) § |
27 |
36 (52) § |
3 |
16.85 (24.65) ‡ |
50 |
0.007 |
<0.001 |
Clinic FEV1 %, mean (SD) |
66.59 (20.77) § |
6 |
67.1 (20.77) § |
2 |
76.78 (23.37) ‡ |
57 |
0.001 |
0.007 |
Maintenance OCS dose, median (IQR) - mg § |
10 (10) |
1 |
10
(10) |
0 |
n/a |
n/a |
n/a |
n/a |
BMI, median (IQR) – kgm-2 ‡ |
30.60 (9.75) |
0 |
28.95 (28.95) |
0 |
30.8 (10.8) |
3 |
0.502 |
0.214 |
Age of asthma diagnosis, median (IQR) - y |
10 (25) |
4 |
28
(38.5) |
1 |
20 (35) |
9 |
0.007 |
0.039 |
Age, median (IQR) - y |
52 (18.5) |
0 |
61 (19) |
0 |
54.5 (25) |
0 |
0.643 |
0.015 |
|
Percentage (N) |
Missing |
Percentage (N) |
Missing |
Percentage (N) |
Missing |
P-value |
P-value |
Multiple AHE (>1), Yes |
31.3% (30) † |
9 |
16.9% (10) † |
3 |
24.3% (43) ‡ |
5 |
0.215 |
0.242 |
On Maintenance OCS, Yes |
47.6% (50) § |
0 |
72.6% (45) § |
0 |
30.6% (53) ‡ |
1 |
0.004 |
<0.001 |
Adult-onset asthma, Yes |
37.6% (38) |
4 |
60.7% (37) |
1 |
52.7% (89) |
9 |
0.017 |
0.282 |
Sex, Male |
33.3% (35) |
0 |
53.2% (33) |
0 |
29.8% (53) |
0 |
0.532 |
0.001 |
Ethnicity, White |
87.6% (92) |
0 |
91.9% (57) |
0 |
94.9%
(169) |
0 |
0.026 |
0.362 |
Rhinitis, Ever ‡ |
73.6% (64) |
18 |
72.9% (43) |
3 |
60.1%
(95) |
10 |
0.035 |
0.082 |
GORD, Ever ‡ |
64.4% (67) |
1 |
67.2% (41) |
1 |
65.3% (111) |
8 |
0.883 |
0.875 |
Smoking, Ever ‡ |
43.8% (46) |
0 |
56.5% (35) |
0 |
47.5%
(84) |
1 |
0.552 |
0.223 |
Atopy (SPT / sIgE positive) ‡ |
100% (105) |
0 |
50.0% (31) |
0 |
52.8% (94) |
0 |
<0.001 |
0.703 |
Obesity (BMI≥30kgm-2), Ever ‡ |
52.4% (55) |
0 |
41.9% (26) |
0 |
52.6% (92) |
3 |
0.975 |
0.097 |
Admitted to ICU for asthma, Ever ‡ |
27.9% (29) |
1 |
35.5%
(22) |
0 |
32.6% (58) |
0 |
0.410 |
0.677 |
Intubated for Asthma, Ever ‡ |
14.4% (15) |
1 |
14.5% (9) |
0 |
17.4% (31) |
0 |
0.512 |
0.598 |
Dysfunctional breathing, Ever ‡ |
51.5% (51) |
6 |
40.0% (24) |
2 |
55.1% (92) |
11 |
0.572 |
0.045 |
ILO, Ever ‡ |
19.4% (18) |
12 |
13.8% (8) |
4 |
13.2% 921) |
19 |
0.193 |
0.911 |
Depression, Ever ‡ |
31.9% (29) |
14 |
28.3% (17) |
2 |
42.8% (68) |
19 |
0.089 |
0.051 |
Anxiety, Ever ‡ |
30.8% (28) |
14 |
27.1% (16) |
3 |
38.0%
(60) |
19 |
0.252 |
0.136 |
Bronchiectasis, Ever ‡ |
15.5% (16) |
2 |
19.4% (12) |
0 |
14.2% (25) |
2 |
0.762 |
0.336 |
Salicylate sensitivity, Ever ‡ |
33.0% (34) |
2 |
19.4% (12) |
0 |
27.8% (49) |
2 |
0.416 |
0.188 |
ABPA, Ever ‡ |
12.6% (13) |
2 |
12.9% (8) |
0 |
5.2% (9) |
4 |
0.027 |
0.081 |
Sulphite sensitivity, Ever ‡ |
8.7% (9) |
2 |
9.7 % (6) |
0 |
7.4% (13) |
3 |
0.696 |
0.590 |
COPD, Ever ‡ |
5.8% (6) |
2 |
9.7 % (6) |
0 |
10.8% (19) |
2 |
0.161 |
0.805 |
Nasal polyps, Ever ‡ |
21.4% (21) |
7 |
34.5% (20) |
4 |
19%
(31) |
15 |
0.635 |
0.019 |
Nasal (polyps / sinus) surgery, Ever ‡ |
31.6% (30) |
10 |
31.7% (19) |
2 |
19.3% (31) |
17 |
0.025 |
0.050 |
Urticaria or Angioedema, Ever ‡ |
12.6% (13) |
2 |
8.1% (5) |
0 |
6.8% (12) |
2 |
0.101 |
0.776 |
OSA, Ever ‡ |
4.9% (5) |
2 |
6.5% (4) |
0 |
11.5% (20) |
4 |
0.062 |
0.259 |
Eczema, Ever ‡ |
31.7% (33) |
1 |
27.4% (17) |
0 |
21.6%
(38) |
2 |
0.060 |
0.349 |